Lista de obras - Julien Taïeb - Dominio Público Uruguay

5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer

artículo científico publicado en 2002

A novel dendritic cell subset involved in tumor immunosurveillance

artículo científico publicado en 2006

Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives

artículo científico publicado en 2015

Advances in management of adjuvant chemotherapy in rectal cancer: Consequences for clinical practice

artículo científico publicado en 2016

An unusual recurrence site for HCC!

artículo científico publicado en 2012

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

artículo científico publicado en 2011

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients

artículo científico publicado en 2016

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

artículo científico publicado en 2018

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

artículo científico publicado en 2013

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

artículo científico publicado en 2005

Case histories in unresectable liver-dominant metastatic colorectal cancer

artículo científico publicado en 2014

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial

artículo científico publicado en 2008

Checkpoint inhibitors and gastrointestinal immune-related adverse events

artículo científico publicado en 2016

Chemosensitivity in ovarian metastases from gastric cancer: a case series

artículo científico publicado en 2012

Colorectal cancer and immunity: what we know and perspectives

artículo científico publicado en 2014

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

artículo científico publicado en 2012

Control of the immune response by pro-angiogenic factors

artículo científico publicado en 2014

DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial

artículo científico

Dendritic cell derived-exosomes: biology and clinical implementations

artículo científico publicado en 2006

Dendritic cell-derived exosomes as cell-free peptide-based vaccines

artículo científico publicado en 2005

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

artículo científico publicado en 2009

Digestive neuroendocrine tumors (DNET): the era of targeted therapies

artículo científico

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy

artículo científico publicado en 2014

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study

artículo científico publicado en 2016

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study

artículo científico publicado en 2015

Exosome-based immunotherapy

artículo científico publicado en 2004

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

artículo científico

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

artículo científico publicado en 2006

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

artículo científico publicado en 2016

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

artículo científico publicado en 2014

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 tri

artículo científico

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

artículo científico publicado en 2008

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

artículo científico publicado en 2007

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

artículo científico publicado en 2003

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study

artículo científico publicado en 2012

Hepatocellular carcinoma (HCC): an update

artículo científico publicado en 2007

Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects

artículo científico

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study

artículo científico publicado en 2005

Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?

artículo científico publicado en 2008

Management of hepatocellular carcinoma. Where are we now? What's next?

artículo científico publicado en 2009

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine

artículo científico publicado en 2011

Modulation of immunity by antiangiogenic molecules in cancer

artículo científico

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors

artículo científico publicado en 2013

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

artículo científico publicado en 2017

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

artículo científico publicado en 2015

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial

artículo científico publicado en 2015

Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma

artículo científico publicado en 2011

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

artículo científico publicado en 2004

Operable colon cancer: initial strategy

artículo científico publicado el 20 de octubre de 2010

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma

artículo científico publicado en 2002

Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort

artículo científico

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).

artículo científico publicado en 2017

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

artículo científico publicado en 2002

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

artículo científico publicado en 2016

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

artículo científico publicado en 2014

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

artículo científico publicado en 2017

Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.

artículo científico publicado en 2016

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

artículo científico publicado en 2017

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

artículo científico publicado en 2016

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

artículo científico publicado en 2015

Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays

artículo científico publicado en 2011

Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge

artículo científico publicado en 2015

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

artículo científico publicado en 2013

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

scientific article published on 09 January 2014

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

artículo científico publicado en 2017

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy

artículo científico publicado en 2014

The IDEA Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX Regimen for Patients with Stage III Colon Cancer: Current Status

artículo científico publicado en 2014

The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.

artículo científico publicado en 2008

The potential of exosomes in immunotherapy

artículo científico publicado en 2005

The potential of exosomes in immunotherapy of cancer

artículo científico publicado en 2005

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

artículo científico publicado en 2007

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

artículo científico publicado en 2017

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer

artículo científico publicado en 2013

Unresectable liver metastases in colorectal cancer: review of current strategies

artículo científico publicado en 2016

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

artículo científico publicado en 2015

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

artículo científico publicado en 2012

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer

artículo científico publicado en 2013

Lista de obras de Julien Taïeb

5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer

A novel dendritic cell subset involved in tumor immunosurveillance

Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives

Advances in management of adjuvant chemotherapy in rectal cancer: Consequences for clinical practice

An unusual recurrence site for HCC!

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

Case histories in unresectable liver-dominant metastatic colorectal cancer

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial

Checkpoint inhibitors and gastrointestinal immune-related adverse events

Chemosensitivity in ovarian metastases from gastric cancer: a case series

Colorectal cancer and immunity: what we know and perspectives

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

Control of the immune response by pro-angiogenic factors

DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial

Dendritic cell derived-exosomes: biology and clinical implementations

Dendritic cell-derived exosomes as cell-free peptide-based vaccines

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

Digestive neuroendocrine tumors (DNET): the era of targeted therapies

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study

Exosome-based immunotherapy

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 tri

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study

Hepatocellular carcinoma (HCC): an update

Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study

Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?

Management of hepatocellular carcinoma. Where are we now? What's next?

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine

Modulation of immunity by antiangiogenic molecules in cancer

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial

Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Operable colon cancer: initial strategy

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma

Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays

Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy

The IDEA Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX Regimen for Patients with Stage III Colon Cancer: Current Status

The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.

The potential of exosomes in immunotherapy

The potential of exosomes in immunotherapy of cancer

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer

Unresectable liver metastases in colorectal cancer: review of current strategies

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer